{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:53:55Z","timestamp":1788836035715,"version":"build-2803163510"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.tem.2019.11.003","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T08:34:27Z","timestamp":1576139667000},"page":"239-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)"],"prefix":"10.1016","volume":"31","author":[{"given":"Krystallenia I.","family":"Alexandraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosmas","family":"Daskalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Tsoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley B.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Kaltsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2019.11.003_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12020-011-9562-2","article-title":"Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy","volume":"41","author":"Alexandraki","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2019.11.003_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.21037\/atm.2018.06.27","article-title":"Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms","volume":"6","author":"Kyriakopoulos","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000471880","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy \u2013 biotherapy and novel targeted agents","volume":"105","author":"Pavel","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.11.003_bib5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature","volume":"70","author":"Gunther","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tem.2019.11.003_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1530\/ERC-15-0490","article-title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study","volume":"23","author":"Caplin","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib7","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows\u00a0efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a Phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib9","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, Phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.tem.2019.11.003_bib10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/MPA.0b013e31821f66b4","article-title":"Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period","volume":"40","author":"Anthony","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.tem.2019.11.003_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ecl.2010.12.010","article-title":"New and emerging syndromes due to neuroendocrine tumors","volume":"40","author":"Vinik","year":"2011","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.tem.2019.11.003_bib12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00280-013-2202-1","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, Phase I study","volume":"72","author":"Wolin","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.tem.2019.11.003_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-14-0360","article-title":"Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors","volume":"22","author":"Cives","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.11.003_bib15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/annonc\/mdx078","article-title":"A randomized, open-label, Phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial","volume":"28","author":"Kulke","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1177\/0091270011408727","article-title":"Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers","volume":"52","author":"Petersenn","year":"2012","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.tem.2019.11.003_bib17","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1572-0241.1998.465_q.x","article-title":"Slow-release lanreotide treatment in endocrine gastrointestinal tumors","volume":"93","author":"Tomassetti","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.tem.2019.11.003_bib18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/02841869109092409","article-title":"Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide","volume":"30","author":"Oberg","year":"1991","journal-title":"Acta Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib19","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.22272","article-title":"Lanreotide Autogel every 6\u00a0weeks compared with lanreotide microparticles every 3\u00a0weeks in patients with well differentiated neuroendocrine tumors: a Phase III study","volume":"107","author":"Bajetta","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib20","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1365-2036.2010.04479.x","article-title":"Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue","volume":"32","author":"Fiebrich","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tem.2019.11.003_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.beem.2015.09.004","article-title":"Neuroendocrine tumours \u2013 medical therapy: biological","volume":"30","author":"Rinke","year":"2016","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2019.11.003_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000456619","article-title":"Impact of vitamin D on the clinical outcome of gastro-entero-pancreatic neuroendocrine neoplasms: report on a series from a single institute","volume":"105","author":"Massironi","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.11.003_bib23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/01635581.2016.1152387","article-title":"Somatostatin analogs and tumor localization do not influence vitamin D concentration in patients with neuroendocrine tumors","volume":"68","author":"Motylewska","year":"2016","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib24","first-page":"24","article-title":"Assessment of fat-soluble vitamins and trace elements in neuroendocrine tumour (NET) patients on somatostatin analogues","volume":"60","author":"Ewang-Emukowhate","year":"2018","journal-title":"Endocr. Abstr."},{"key":"10.1016\/j.tem.2019.11.003_bib25","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.beem.2009.08.003","article-title":"Drugs that suppress TSH or cause central hypothyroidism","volume":"23","author":"Haugen","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2019.11.003_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/17446651.2019.1571909","article-title":"An update on clinical care for pregnant women with acromegaly","volume":"14","author":"Chanson","year":"2019","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2019.11.003_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib28","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gut.38.3.430","article-title":"Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours","volume":"38","author":"Arnold","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.tem.2019.11.003_bib29","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib30","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with\u00a0metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.tem.2019.11.003_bib31","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib32","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1023\/A:1008205415035","article-title":"High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical\u00a0and biological effects","volume":"8","author":"Eriksson","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib33","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms","volume":"17","author":"Wymenga","year":"1999","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.11.003_bib35","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bpg.2013.01.001","article-title":"Biotherapies for GEP-NETs","volume":"26","author":"Oberg","year":"2012","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.tem.2019.11.003_bib36","first-page":"1297","article-title":"Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results","volume":"70","author":"Oberg","year":"1986","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.tem.2019.11.003_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000443170","article-title":"ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum","volume":"103","author":"Niederle","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.11.003_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7326\/0003-4819-115-3-178","article-title":"Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors","volume":"115","author":"Ronnblom","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/02841869109092414","article-title":"Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment","volume":"30","author":"Ronnblom","year":"1991","journal-title":"Acta Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/014107680309601003","article-title":"Interferon alpha treatment and endocrine disease","volume":"96","author":"Chan","year":"2003","journal-title":"J.\u00a0R. Soc. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib41","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, Phase III RADIANT-3 study","volume":"34","author":"Yao","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MPA.0000000000000262","article-title":"Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the Phase III RADIANT-3 trial","volume":"44","author":"Lombard-Bohas","year":"2015","journal-title":"Pancreas"},{"key":"10.1016\/j.tem.2019.11.003_bib43","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, Phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tem.2019.11.003_bib44","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib46","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1634\/theoncologist.2014-0037","article-title":"Real-world study of everolimus in advanced progressive neuroendocrine tumors","volume":"19","author":"Panzuto","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.tem.2019.11.003_bib47","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1530\/EC-19-0134","article-title":"Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms","volume":"8","author":"Daskalakis","year":"2019","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.tem.2019.11.003_bib48","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1634\/theoncologist.2010-0222","article-title":"Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues","volume":"16","author":"Fiebrich","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.tem.2019.11.003_bib49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/qjmed\/hcr249","article-title":"IGF2-induced hypoglycemia unresponsive to everolimus","volume":"107","author":"Korevaar","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.tem.2019.11.003_bib50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1056\/NEJMc0806740","article-title":"Glycemic control in patients with insulinoma treated with everolimus","volume":"360","author":"Kulke","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib51","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1634\/theoncologist.2015-0420","article-title":"Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature","volume":"21","author":"Faggiano","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.tem.2019.11.003_bib52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1634\/theoncologist.2017-0622","article-title":"Phase II study of everolimus and octreotide LAR in patients with nonfunctioning gastrointestinal neuroendocrine tumors: the GETNE1003_EVERLAR study","volume":"24","author":"Capdevila","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.tem.2019.11.003_bib53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejphar.2016.02.064","article-title":"Electrolyte disorders associated with the use of anticancer drugs","volume":"777","author":"Liamis","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tem.2019.11.003_bib54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1507\/endocrj.K10E-130","article-title":"Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma","volume":"57","author":"Sato","year":"2010","journal-title":"Endocr. J."},{"key":"10.1016\/j.tem.2019.11.003_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1620\/tjem.222.39","article-title":"Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume","volume":"222","author":"Sakurai","year":"2010","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib56","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2265.2008.03253.x","article-title":"Thyrotoxicosis during sunitinib treatment for renal cell carcinoma","volume":"69","author":"Grossmann","year":"2008","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.tem.2019.11.003_bib57","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/jc.2011-1172","article-title":"Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression","volume":"96","author":"Kappers","year":"2011","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2019.11.003_bib58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib59","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.2015.196","article-title":"Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma","volume":"113","author":"Gore","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib61","first-page":"000105","article-title":"Sunitinib induced hypocalcemia and its potential role in the treatment of refractory hypercalcemia","volume":"1","author":"Alexandraki","year":"2017","journal-title":"Open Access J. Endocrinol."},{"key":"10.1016\/j.tem.2019.11.003_bib62","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1002\/cncr.26216","article-title":"A Phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies","volume":"117","author":"Wuthrick","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib63","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1530\/ERC-16-0008","article-title":"A Phase II study of axitinib in advanced neuroendocrine tumors","volume":"23","author":"Strosberg","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib64","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tem.2019.11.003_bib65","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2013.470","article-title":"Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours","volume":"109","author":"Ahn","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib66","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","article-title":"Pazopanib in pretreated advanced neuroendocrine tumors: a Phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)","volume":"26","author":"Grande","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib67","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","article-title":"Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, Phase 2 study","volume":"16","author":"Phan","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib68","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/jco.2007.25.18_suppl.4504","article-title":"MC044h, a Phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study","volume":"25","author":"Hobday","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib69","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.ejca.2013.06.042","article-title":"Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a Phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)","volume":"49","author":"Castellano","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib70","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00280-013-2118-9","article-title":"Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors","volume":"71","author":"Chan","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.tem.2019.11.003_bib71","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.semnuclmed.2015.12.003","article-title":"Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer","volume":"46","author":"Bodei","year":"2016","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib72","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib73","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1530\/ERC-18-0424","article-title":"Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study","volume":"26","author":"Carlsen","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2016.01.009","article-title":"Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: a multi-institutional registry study with prospective follow-up","volume":"58","author":"Horsch","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib75","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/s-0032-1314859","article-title":"Differential expression of somatostatin receptor subtype 1\u20135 proteins in numerous human normal tissues","volume":"120","author":"Unger","year":"2012","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.tem.2019.11.003_bib76","first-page":"61","article-title":"Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions","volume":"54","author":"Prasad","year":"2010","journal-title":"Q.\u00a0J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tem.2019.11.003_bib77","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000371806","article-title":"Aggressive pituitary tumors","volume":"101","author":"Chatzellis","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.11.003_bib78","first-page":"39","article-title":"Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using 90yttrium and 177lutetium labeled somatostatin analogs: toxicity, response and survival analysis","volume":"4","author":"Budiawan","year":"2013","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tem.2019.11.003_bib79","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","article-title":"Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors","volume":"23","author":"Kwekkeboom","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib80","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1007\/s00259-009-1151-8","article-title":"Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function","volume":"36","author":"Teunissen","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tem.2019.11.003_bib81","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","author":"Cremonesi","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tem.2019.11.003_bib82","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib84","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib85","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and\u00a0nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, Phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib86","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side-effects of immunotherapy","volume":"26","author":"Castinetti","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib87","article-title":"Endocrinopathies: the new price of cancer treatment","author":"Kotwal","year":"2019","journal-title":"Medscape"},{"key":"10.1016\/j.tem.2019.11.003_bib88","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000473892","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms. Systemic therapy 2: chemotherapy","volume":"105","author":"Garcia-Carbonero","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.11.003_bib89","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.11.003_bib90","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib91","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin\u2013doxorubicin, streptozocin\u2013fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.tem.2019.11.003_bib92","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.ejca.2015.04.005","article-title":"Streptozocin\/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours","volume":"51","author":"Dilz","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib93","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11154-017-9432-1","article-title":"Chemotherapy in NETs: when and how","volume":"18","author":"Angelousi","year":"2017","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.tem.2019.11.003_bib94","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib95","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000500135","article-title":"Activity and safety of standard and prolonged capecitabine\/temozolomide administration in patients with advanced neuroendocrine neoplasms","volume":"109","author":"Chatzellis","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.11.003_bib96","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ejca.2013.12.011","article-title":"Capecitabine and streptozocin\u00a0+\/\u2212 cisplatin in advanced gastroenteropancreatic neuroendocrine tumours","volume":"50","author":"Meyer","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib97","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/ERC-15-0075","article-title":"Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma","volume":"22","author":"Hadoux","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib98","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/ERC-12-0002","article-title":"FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide\u2013platinum combination in patients with neuroendocrine carcinomas grade 3","volume":"19","author":"Hentic","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib99","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4137\/CMRH.S10848","article-title":"Fertility preservation options after gonadotoxic chemotherapy","volume":"7","author":"Hyman","year":"2013","journal-title":"Clin. Med. Insights Reprod. Health"},{"key":"10.1016\/j.tem.2019.11.003_bib100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(05)70092-9","article-title":"Fertility preservation for\u00a0young patients with cancer: who is at risk and\u00a0what can be offered?","volume":"6","author":"Wallace","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tem.2019.11.003_bib101","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.gyobfe.2010.09.002","article-title":"[Unknown gonadotoxicity chemotherapy and preservation of fertility: example of temozolomide]","volume":"38","author":"Sitbon Sitruk","year":"2010","journal-title":"Gynecol. Obstet. Fertil."},{"key":"10.1016\/j.tem.2019.11.003_bib102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MED.0000000000000031","article-title":"Proton pump inhibitor therapy and potential long-term harm","volume":"21","author":"Corleto","year":"2014","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.tem.2019.11.003_bib103","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/2042098617715381","article-title":"Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence","volume":"8","author":"Maes","year":"2017","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.tem.2019.11.003_bib104","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2165\/00002018-200730060-00006","article-title":"Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System","volume":"30","author":"Carvajal","year":"2007","journal-title":"Drug Saf."},{"key":"10.1016\/j.tem.2019.11.003_bib105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","author":"Jensen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.tem.2019.11.003_bib106","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2019.11.003_bib107","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment\u00a0of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J.\u00a0Clin. Oncol."}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276019302255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276019302255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:40:04Z","timestamp":1760906404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276019302255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1043276019302255"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2019.11.003","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2019.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}